Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04706962 · ClinicalTrials.gov registry record · Phase 1
TH1902 in Patients With Advanced Solid Tumors
A Phase 1 study of Prostate Cancer and Solid Tumor, sponsored by Theratechnologies.
- Active
- Registry status
- Phase 1
- Development phase
- 70
- Enrollment target
- 6
- Study locations
NCT04706962 is a Phase 1 study of Prostate Cancer and Solid Tumor that is active but no longer recruiting, run by Theratechnologies. The registered enrollment target is 70 participants, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (88% lower). The trial reports 6 study locations across 4 states.
The verdict
NCT04706962, a Phase 1 study of Prostate Cancer and Solid Tumor, is active but no longer recruiting, sponsored by Theratechnologies.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 70 participants
- Enrollment target
- 6
- Study locations
Study Summary
Open label first-in-human study of TH1902 in solid cancer, with 4 sequential parts: Part 1 (dose escalation): patients with recurrent advanced solid tumors (all comers) that have relapsed or are refractory to standard chemotherapy, surgery, radiation therapy, and for which no known effective therapies exist. Part 2 (expansion): selected patient populations with recurrent advanced TNBC, HR+ breast cancer, epithelial ovarian cancer, endometrial cancer, cutaneous melanoma, thyroid cancer, SCLC, prostate cancer and other cancers known to express SORT1 that are refractory to standard therapy. Part 3 (optimization): patients diagnosed with histologically or cytologically confirmed high grade serous ovarian cancer, including high grade peritoneal or fallopian tube cancer, or high grade endometrioid cancer, that is refractory or resistant to standard therapies, should not be considered platinum sensitive, and where current therapy is not considered to be providing benefit. Part 4 (basket expansion): selected cancer type diagnosed with histologically or cytologically confirmed cancers, where TH1902 has been studied and/or showed activity (in Parts 1 to 3), that is refractory or resistant to standard therapies, and where current therapy is not considered to be providing benefit.
Conditions Studied
Interventions
- DRUG TH1902
Study Locations (6)
Michigan
- Karmanos Cancer Institute - Detroit
- START Midwest - Grand Rapids
Texas
- Mary Crowley Cancer Research - Dallas
- University of Texas MD Anderson Cancer Center - Houston
Pennsylvania
- Pennsylvania Cancer Specialists Research Institute - Gettysburg
Quebec
- Centre Hospitalier de l'Université de Montréal (CHUM) - Montreal
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 70 participants |
| Start Date | 2021-03-04 |
| Est. Completion | 2026-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04706962
The ClinicalTrials.gov registry entry for NCT04706962 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 70 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (88% lower). The listed sponsor is Theratechnologies, which has 7 total studies on file at ClinicalTrials.gov.
The record links to 10 conditions, with Prostate Cancer appearing as the primary indexed condition, and to 1 intervention - of which TH1902 is the first listed.
NCT04706962 reports 6 study locations spanning 4 distinct geographic areas - top geographies include Michigan, Texas, Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT04706962 about?
NCT04706962 is a clinical study titled "TH1902 in Patients With Advanced Solid Tumors". Open label first-in-human study of TH1902 in solid cancer, with 4 sequential parts: Part 1 (dose escalation): patients with recurrent advanced solid tumors (all comers) that have relapsed or are refractory to standard chemotherapy, surgery, radiation therapy, and for which no known effective therap...
What is the current status of trial NCT04706962?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 70 participants. The study started on 2021-03-04. Estimated completion is 2026-01.
What conditions does trial NCT04706962 study?
This clinical trial studies the following conditions: Prostate Cancer, Solid Tumor, Endometrial Cancer, Small-cell Lung Cancer, Thyroid Cancer.
What interventions are being tested in trial NCT04706962?
The interventions under investigation include: TH1902 (DRUG).
Who is sponsoring clinical trial NCT04706962?
This trial is sponsored by Theratechnologies, which has 7 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04706962 being conducted?
This trial has 6 study locations across Michigan, Pennsylvania, Texas, Quebec. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Prostate Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Evaluate Safety, Efficacy, and Pharmacokinetics in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
-
Phase 1 Trial of ZM008 as Single Agent and in Combination With Pembrolizumab in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
-
Study of JANX007 in Subjects With Metastatic Castration-Resistant Prostate Cancer (ENGAGER-PSMA-01)
RECRUITING · Phase 1
-
Study of STM-416p Administered to Patients Undergoing Radical Prostatectomy
RECRUITING · Phase 1
-
A Study to Learn How Safe AZD6621 is, How Well it Works, and How it Moves Throughout the Body Over Time, in Adult Male Participants With Metastatic Prostate Cancer
RECRUITING · Phase 1
-
Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.